Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim

Last Updated: January 23, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Tremelimumab

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the development status for investigational drug Tremelimumab?

Tremelimumab is an investigational drug.

There have been 141 clinical trials for Tremelimumab. The most recent clinical trial was a Phase 2 trial, which was initiated on January 1st 2015.

The most common disease conditions in clinical trials are Carcinoma, Lung Neoplasms, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are AstraZeneca, MedImmune LLC, and M.D. Anderson Cancer Center.

There are fifty-four US patents protecting this investigational drug and one international patent.

Recent Clinical Trials for Tremelimumab
Trial of Neoadjuvant Durvalumab Plus Docetaxel, Oxaliplatin, S-1 Followed by Surgery and Adjuvant Durvalumab Plus S-1 Chemotherapy in Potentially Resectable MMR Proficient Gastric or Gastroesophageal Junction AdenocarcinomaAsan Medical CenterPhase 2
Programmed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic MelanomaYale UniversityEarly Phase 1
Progression-free Survival After MWA Plus Durvalumab and Tremelimumab for Unresectable Locally Advanced Pancreatic CancerAstraZenecaPhase 2

See all Tremelimumab clinical trials

Clinical Trial Summary for Tremelimumab

Top disease conditions for Tremelimumab
Top clinical trial sponsors for Tremelimumab

See all Tremelimumab clinical trials

US Patents for Tremelimumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Tremelimumab   Start Trial Immunoregulatory agents Flexus Biosciences, Inc. (Princeton, NJ)   Start Trial
Tremelimumab   Start Trial .beta.-glucan methods and compositions that affect the tumor microenvironment BIOTHERA, INC. (Eagan, MN)   Start Trial
Tremelimumab   Start Trial Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein CureVac AG (Tubingen, DE)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.